Aurobindo Pharma
Aurobindo Pharma Limited, commonly known as Aurobindo Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1986, the company has established a strong presence in over 150 countries, with significant operations across North America, Europe, and Asia. Specialising in the manufacture of generic pharmaceuticals, Aurobindo Pharma offers a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company is recognised for its commitment to quality and innovation, which has propelled it to a leading position in the market. With numerous regulatory approvals and a robust pipeline of products, Aurobindo Pharma continues to achieve notable milestones, solidifying its reputation as a trusted provider of affordable healthcare solutions worldwide.
DitchCarbon Score
How does Aurobindo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurobindo Pharma's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aurobindo Pharma's reported carbon emissions
In 2024, Aurobindo Pharma reported total carbon emissions of approximately 967,471,000 kg CO2e, comprising 414,356,000 kg CO2e from Scope 1 and 553,115,000 kg CO2e from Scope 2. This marks a slight decrease from 2023, where total emissions were about 941,472,000 kg CO2e, with Scope 1 at 447,207,000 kg CO2e and Scope 2 at 494,264,000 kg CO2e. The company has set ambitious climate commitments, aiming for a 12.5% reduction in its carbon footprint for both Scope 1 and Scope 2 emissions by 2025, in line with the Science Based Targets initiative (SBTi) for a well below 2°C scenario. This target reflects Aurobindo Pharma's commitment to sustainability and reducing its environmental impact. Aurobindo Pharma does not currently disclose Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. The company’s emissions data is not cascaded from any parent organization, indicating that it independently reports its carbon footprint and climate initiatives. Overall, Aurobindo Pharma is actively working towards reducing its carbon emissions while maintaining transparency in its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aurobindo Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
